- Home
- APXT vs IRWD Comparison
APXT vs IRWD Comparison
Compare APXT & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APXT | IRWD |
|---|---|---|
| Founded | 2025 | 1998 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 457.3M | 526.7M |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | APXT | IRWD |
|---|---|---|
| Price | $10.00 | $4.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 27.4K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | ★ N/A | $29.57 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $9.87 | $0.55 |
| 52 Week High | $10.00 | $5.78 |
Technical Indicators
Market Signals| Indicator | APXT | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 56.97 | 67.45 |
| Support Level | N/A | $3.07 |
| Resistance Level | $10.00 | $5.67 |
| Average True Range (ATR) | 0.01 | 0.22 |
| MACD | 0.00 | 0.13 |
| Stochastic Oscillator | 92.86 | 95.12 |
Price Performance
Historical ComparisonAbout APXT Apex Treasury Corporation Class A Ordinary Share
Apex Treasury Corp is a blank check company established for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.